PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
MIDLOTHIAN, Va., June 30 /PRNewswire/ -- In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function.
"We are pleased that researchers chose PARI products as the exclusive nebulizer systems for recent studies comparing maintenance treatments for COPD. Sutherland et al. used an open-label crossover design allowing researchers to catalog patient preferences regarding medication delivery. Patients felt greater treatment satisfaction and perceived better control of their COPD with nebulized formoterol fumarate delivered by PARI's LC Plus and PRONEB Ultra II. These results are consistent with other studies," said Lisa Cambridge, RRT, director of clinical development at PARI Respiratory Equipment.
The Sutherland et al. study, published in Current Medical Research and Opinion, compared nebulized formoterol fumarate to ipratropium/albuterol delivered via a metered dose inhaler. The study concluded that nebulized formoterol fumarate significantly improved pulmonary function and was more satisfactory to COPD patients than treatment with ipratropium/albuterol delivered via MDI.
The Tashkin et al. study, presented at the American Thoracic Society conference last month, looked at the effectiveness of adding nebulized formoterol fumarate, delivered via PARI's LC Plus and PRONEB Ultra, to maintenance tiotropium compared to placebo/tiotropium. The study concluded that adding nebulized formoterol fumarate to maintenance tiotropium in COPD subjects provided significant improvements in pulmonary function, dyspnea, and rescue albuterol use over tiotropium alone. The incidence of adverse events was lower during treatment with formoterol/tiotropium compared to placebo/tiotropium.
The PARI LC Plus nebulizer and PARI PRONEB Ultra compressor were used exclusively in pivotal clinical trials for Perforomist Inhalation Solution and are listed in the package insert.
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.
Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com
Additional information is available by contacting Kirsten Ayars at 805-845-5682 or Ashley Weigand at 804-253-7274 x711.
